EXACT Therapeutics announces grant of key patent covering non-invasive delivery of pharmaceuticals to the brain

EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology, has been informed that the Intellectual Property Office in the United Kingdom has granted EXACT’s United Kingdom Patent no. 2104590.1 entitled “Treatment of the central nervous system”.

The granted patent covers EXACT’s proprietary Acoustic Cluster Therapy (ACT®) for the treatment of diseases of the central nervous system (CNS), including the brain.

Per Walday, CEO of EXACT, comments, ”We are thrilled to announce the granting of this patent in its first territory, marking an important milestone for the development of ACT. The blood-brain barrier has long posed a major challenge to delivering treatments to the brain. Our ACT technology may open exciting new possibilities by enabling access to larger brain areas and paving the way for more effective therapies. One of the most compelling applications is in glioblastoma – the most common form of brain cancer – where we recently reported encouraging non-clinical results.”

About Exact Therapeutics

EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here:          www.exact-tx.com   

For further information, please contact:

Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com